Eli Lilly

Latest Headlines

After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their testosterone sales to suffer in 2015. But as the mainstream medical community apparently moves away from testosterone replacement meds, specialized clinics are taking up the charge.

After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their testosterone sales to suffer in 2015. But as the mainstream medical community apparently moves away from testosterone replacement meds, specialized clinics are taking up the charge.

For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.

Kees Been has banked the $20 million round needed to move a bold new development program for delaying or preventing Parkinson's toward the clinic. And the veteran biotech CEO at the helm of Lysosomal Therapeutics Inc. is moving forward with a group of high-profile backers in his corner.

Eli Lilly CEO John Lechleiter promised today that the company's finances will improve over the next decade. It would be hard for them to get much worse. Lilly's fourth-quarter net income was down 41%. Its revenue was down 12%. Its earnings were down 40% to $0.40 a share.

Box has added a big-name client just days after pulling off a $175 million IPO. The deal sees AstraZeneca join Allergan and Eli Lilly on the list of major biopharma companies that use Box's cloud content sharing and collaboration tools.

Earlier this month the FDA stopped a shipment of what it believed to be Cialis manufactured in Australia that it said contained improper ingredients. Cialis maker Eli Lilly, however, said the product appeared to be counterfeit. It made no Cialis in Australia. Now the FDA is saying it has found Cialis fakes being shipped in the mail and is warning consumers to beware.

The hepatitis C payer negotiations may be making the biggest headlines these days, but diabetes contracts were making headlines first. And if Eli Lilly & Co. and its drugs are any indication, those headlines are likely to continue.

Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.

Join 150,000+ InsidersSIGN UP FOR OURNEWSLETTER

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get FiercePharma via daily email. Sign up today!

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!